Iomai Corp. [IOMI] says it has won a one-year cost-reimbursement grant for up to $943,856 from the Army Medical Research and Materiel Command to perform preclinical work on a patch-based version of the anthrax vaccine. Iomai will use vaccine antigen developed by United Kingdom-based Avecia Biologics Ltd. and apply its technology to formulate a dry version of the antigen that can be combined with an Iomai adjuvant on a needle-free patch. Iomai will then evaluate the stability of the patch…
Recommended
DHS IG Dings Coast Guard FRC Program For Operational Shortcomings
Coast Guard Buys Its Own MQ-9B Long-Range UAS
Trending
Congress Updates
Hegseth Pushes For Reconciliation With At Least $350 Billion For Defense ‘Regardless’ Of Midterms Outcome
Defense Secretary Pete Hegseth said Wednesday the Trump administration plans to continue its push for at least $350 billion in defense funds via the reconciliation process “regardless of what happens […]
Bipartisan Push in Senate to Hasten Export of 155 mm, GMLRS, HIMARS for Ukraine
A small, bipartisan group of senators is backing the Fast Tracking European Investment in Ukraine’s Defense Act, S. 5175, to hasten the export of allied buys of U.S. munitions for […]
Rep. Himes Signals Increased Contractor Oversight, if Democrats Win House
Rep. Jim Himes (D-Conn.), the ranking member of the House Permanent Select Committee on Intelligence, plans to increase the committee’s contractor oversight if the Democrats win control of the House […]
CBO Estimates Loss of One-Half to Two-Thirds of U.S. Missile Interceptors Since June Last Year
A new Congressional Budget Office report estimates the cost of the Iran war through Aug. 1 as $38 billion and says that the U.S. has likely depleted between one-half and […]